In this issue:
PD-L1 expression as a biomarker increases immunotherapy cost-effectiveness
Advantages of ctDNA versus tumour tissue analysis
Consider tumour sidedness in RAS wt mCRC
CAP-B maintenance treatment effective in all mCRC mutational subgroups
Changes in ctDNA levels in mCRC predict treatment efficacy?
Elderly fare worse than younger patients on CRT for NSCLC
Modifying dietary fat intake may reduce lung cancer risk
Updated ASCO guidelines for treating resected stage I–IIIA NSCLC
Dabrafenib + trametinib in BRAF V600E-mutant NSCLC
Surgery after concurrent CRT in oesophageal cancer
Please login below to download this issue (PDF)